Last A$0.94 AUD
Change Today +0.01 / 1.08%
Volume 2.6M
SIP On Other Exchanges
Symbol
Exchange
OTC US
Berlin
OTC US
As of 12:11 AM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

sigma pharmaceuticals ltd (SIP) Snapshot

Open
A$0.93
Previous Close
A$0.93
Day High
A$0.95
Day Low
A$0.92
52 Week High
03/3/15 - A$0.95
52 Week Low
03/25/14 - A$0.61
Market Cap
1.0B
Average Volume 10 Days
2.2M
EPS TTM
A$0.06
Shares Outstanding
1.1B
EX-Date
04/3/14
P/E TM
17.1x
Dividend
A$0.03
Dividend Yield
3.04%
Current Stock Chart for SIGMA PHARMACEUTICALS LTD (SIP)

Related News

No related news articles were found.

sigma pharmaceuticals ltd (SIP) Related Businessweek News

No Related Businessweek News Found

sigma pharmaceuticals ltd (SIP) Details

Sigma Pharmaceuticals Limited is engaged in the wholesale and distribution of pharmaceutical products to hospitals and retail pharmacies in Australia. It operates approximately 300 pharmacies under the Amcal name; and 150 pharmacies under the Guardian name. The company also offers health management services, including professional advice; and tailored products in the areas of heart health, bones and joints, diabetes, and respiration under the Amcal Max name. In addition, it manages and promotes a range of over the counter private and exclusive label products made available to brand member customers, as well as a generic range of private label products under the Pharmacy Care range. Sigma Pharmaceuticals Limited was founded in 1912 and is headquartered in Rowville, Australia.

Founded in 1912

sigma pharmaceuticals ltd (SIP) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: A$1.3M
Chief Financial Officer
Total Annual Compensation: A$498.5K
Chief Operating Officer
Total Annual Compensation: A$570.9K
Compensation as of Fiscal Year 2014.

sigma pharmaceuticals ltd (SIP) Key Developments

Sigma Pharmaceuticals Limited Provides Revenue Guidance for the Fiscal 2016

Sigma Pharmaceuticals Limited provided revenue guidance for the fiscal 2016. The company confirmed that it remains on track to deliver significant revenue gains in the fiscal 2016 following a string of announcements that have positioned the business as the market leader in the wholesale pharmaceutical business in Australia.

Sigma Pharmaceuticals Limited Launches Coeliac Disease Screening Test in Australia

Sigma Pharmaceuticals Limited has launched the new SIMTOMAX coeliac in-pharmacy screening test for coeliac disease in Australia. The new test, which involves a small finger prick blood sample, will be available exclusively at Amcal, Amcal Max and Guardian pharmacies from October 9, 2014.

Sigma Pharmaceuticals Ltd. Announces Unaudited Consolidated Earnings Results for the First Half Year Ended July 31, 2014

Sigma Pharmaceuticals Ltd. announced unaudited consolidated earnings results for the first half year ended July 31, 2014. For the period, the company reported sales revenues of AUD 1,502,208,000 compared with AUD 1,463,813,000 for the same period a year ago. EBITDA was AUD 37,079,000 compared with AUD 28,098,000 for the same period a year ago. EBIT was AUD 33,458,000 compared with AUD 24,876,000 for the same period a year ago. Net profit after tax was AUD 22,394,000 or 2.1 cents per diluted share compared with AUD 16,283,000 or 1.4 cents per diluted share for the same period a year ago. Profit before tax was AUD 32,796,000 compared with AUD 23,717,000 for the same period a year ago. Net profit for the period attributable to members was AUD 22,394,000 compared with AUD 16,283,000 for the same period a year ago. Net cash flow from operating activities was AUD 18,826,000 compared with AUD 4,767,000 for the same period a year ago. Payments for property, plant and equipment and software was AUD 2,261,000 compared with AUD 4,539,000 for the same period a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SIP:AU A$0.94 AUD +0.01

SIP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SIP.
View Industry Companies
 

Industry Analysis

SIP

Industry Average

Valuation SIP Industry Range
Price/Earnings 14.1x
Price/Sales 0.3x
Price/Book 1.5x
Price/Cash Flow 12.7x
TEV/Sales 0.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SIGMA PHARMACEUTICALS LTD, please visit www.sigmaco.com.au. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.